国海证券指出，LP-003可覆盖多种适应症，产品针对多种适应症的IND批准及/或启动相关临床试验，包括季节性AR、CSU、过敏性哮喘、CRSwNP及食物过敏。此外，LP-003 II期临床数据初步展现出超越奥马珠单抗的潜力。根据医药魔方，LP-003 200mg Q8W组在首要临床指标“12周等麻疹活动度评分UAS7=0的比例(Proportion of Patients with UAS7=0 at Week 12)”、以及12周的UAS7较基线变化(UAS7 LS Mean Change from baseline at week 12)上，显著优于奥马珠单抗。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.